What Financial Crisis? Australian Biotech Enters Golden Era (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Australia's biotech sector has entered a golden era, with its top 20 companies now maturing, for the first time bringing products to late-stage development, and looking to commercialize
You may also be interested in...
Australia's New R&D Tax Credit Expected To Inject Funds Into Local Biotech Industry - And Multinational Subsidiaries?
MELBOURNE, Australia - Many in the Australian life sciences industry view the nation's new R&D Tax Credit, which became law in August 2011 with the passing of the Tax Laws Amendment (Research and Development) Bill 2010, as a marked improvement on the R&D Tax Concession it replaces
Australia's New R&D Tax Credit Expected To Inject Funds Into Local Biotech Industry - And Multinational Subsidiaries?
MELBOURNE, Australia - Many in the Australian life sciences industry view the nation's new R&D Tax Credit, which became law in August 2011 with the passing of the Tax Laws Amendment (Research and Development) Bill 2010, as a marked improvement on the R&D Tax Concession it replaces
What Financial Crisis? Australian Biotech Enters Golden Era (Part 2 of 2)
PERTH, Australia - As Australia's biotech sector comes of age, it is beginning to attract the attention of multinational companies, as evidenced by stepped-up merger and acquisition activity and rounds of new funding in the last six months